Get the Stockscreener App
52.22
0.38%
0.20
After Hours:
51.19
-1.03
-1.97%
Cytokinetics Inc stock is traded at $52.22, with a volume of 769.91K.
It is up +0.38% in the last 24 hours and up +1.75% over the past month.
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$52.02
Open:
$52.03
24h Volume:
769.91K
Relative Volume:
0.65
Market Cap:
$6.14B
Revenue:
$3.13M
Net Income/Loss:
$-545.28M
P/E Ratio:
-9.4601
EPS:
-5.52
Net Cash Flow:
$-401.27M
1W Performance:
+4.73%
1M Performance:
+1.75%
6M Performance:
+8.12%
1Y Performance:
+64.06%
1-Day Range:
$51.66
$52.84
1-Week Range:
$47.41
$52.84
52-Week Range:
$30.68
$110.25
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
52.22 | 6.14B | 3.13M | -545.28M | -401.27M | -5.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Great Point Partners LLC - MarketBeat
Algert Global LLC Sells 22,738 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics director Wendall Wierenga sells $37,100 in stock By Investing.com - Investing.com Nigeria
Insider Sell Alert: Fady Malik Sells 7,300 Shares of Cytokinetics Inc (CYTK) - GuruFocus.com
Cytokinetics EVP sells shares worth $366,181 By Investing.com - Investing.com Canada
Cytokinetics EVP sells shares worth $366,181 - Investing.com
Cytokinetics director Wendall Wierenga sells $37,100 in stock - Investing.com
Intech Investment Management LLC Invests $1.73 Million in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Purchased by Massachusetts Financial Services Co. MA - MarketBeat
Westfield Capital Management Co. LP Purchases 339,373 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Swiss National Bank Buys 20,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Hypertrophic Cardiomyopathy Pipeline 2024: Clinical Trials - openPR
Cytokinetics price target raised to $103 from $99 at Mizuho - Yahoo Finance
Ontario Teachers Pension Plan Board Takes Position in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan - MSN
Why Is Cytokinetics, Incorporated (CYTK) Among the Worst Performing Biotech Stocks in 2024? - Insider Monkey
Cytokinetics (NASDAQ:CYTK) Given New $103.00 Price Target at Mizuho - MarketBeat
Cytokinetics' (CYTK) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Bayer acquires rights to Cytokinetics' heart drug in Japan - MSN
Cytokinetics and Bayer ink deal for aficamten in Japan - The Pharma Letter
Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates - MSN
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Acquired by Royce & Associates LP - MarketBeat
Cytokinetics CEO Robert Blum sells shares for $252,750 - Investing.com
Cytokinetics CEO Robert Blum sells shares for $252,750 By Investing.com - Investing.com Canada
Bayer (BAYRY) and Cytokinetics (CYTK) Collaborate on Japanese HC - GuruFocus.com
Cytokinetics, Bayer in Japan Licensing Pact for Aficamten - MarketWatch
Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer - Yahoo Finance
First Turn Management LLC Sells 70,171 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan - Yahoo Finance
Bayer: exclusive licensing agreement with Cytokinetics in Japan - Marketscreener.com
Bayer secures rights to heart drug in multi-million deal - Marketscreener.com
Cytokinetics Lands €50M Bayer Deal for HCM Drug Aficamten in Japan, €580M+ Potential | CYTK Stock News - StockTitan
H.C. Wainwright keeps Buy rating on Cytokinetics shares, citing promising data on aficamten and omecamtiv - Investing.com Canada
Cytokinetics' (CYTK) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024 - The Manila Times
Cytokinetics' Aficamten Shows 90% Drop in Heart Surgery Need, Major QoL Gains in HCM Study | CYTK Stock News - StockTitan
Principal Financial Group Inc. Sells 120,497 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024 - Marketscreener.com
Significant Portfolio Addition: T. Rowe Price Investment Managem - GuruFocus.com
Insider Sale at Cytokinetics Inc (CYTK): EVP Research & Developm - GuruFocus.com
Cytokinetics: On The Cusp Of Commercialization (NASDAQ:CYTK) - Seeking Alpha
Cytokinetics EVP sells $370,880 in stock By Investing.com - Investing.com Nigeria
Cytokinetics EVP sells $370,880 in stock - Investing.com
Cytokinetics' SWOT analysis: cardiac drug maker's stock poised for growth - Investing.com
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives $83.67 Average Price Target from Brokerages - MarketBeat
FMR LLC Bolsters Stake in Cytokinetics Inc - GuruFocus.com
Cytokinetics to Present at Jefferies London Healthcare Conference 2024 | CYTK Stock News - StockTitan
Lisanti Capital Growth LLC Sells 26,800 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics, Incorporated Announces Initiation of Phase 1 Clinical Study of CK-4015089 - Marketscreener.com
Cytokinetics Launches Phase 1 Trial for Novel Muscle Function Drug CK-089 | CYTK Stock News - StockTitan
Abstract 4142906: Efficacy and Safety of Aficamten in Patients Guideline-Eligible for Septal Reduction Therapy in the FOREST-HCM Trial - AHA Journals
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytokinetics Inc Stock (CYTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Nov 26 '24 |
Sale |
50.16 |
7,300 |
366,181 |
111,878 |
| WIERENGA WENDALL | Director |
Nov 25 '24 |
Option Exercise |
7.37 |
742 |
5,469 |
25,301 |
| WIERENGA WENDALL | Director |
Nov 25 '24 |
Sale |
50.00 |
742 |
37,100 |
24,559 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):